Search research articles
Contact Us
Filters
Showing results (151-160 of 174) with videos related to
Page
of 18
Sort By:
American Journal of Hematology
|
December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study
Marie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Neuro-Oncology
|
March 9, 2016
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study
Caroline Houillier, Sylvain Dureau, Luc Taillandier, et al.
The Lancet. Haematology
|
December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with <sup>90</sup>Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
Françoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.
British Journal of Haematology
|
July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS
Emma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
British Journal of Haematology
|
April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
María Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Oncotarget
|
July 27, 2016
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Emilie Reboursiere, Fabien Le Bras, Charles Herbaux, et al.
Blood Advances
|
October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry
Federico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.
Leukemia
|
September 14, 2022
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML
Arsene Mekinian, Lin Pierre Zhao, Sylvie Chevret, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 174) with videos related to
Sort By:
Page
of 18
American Journal of Hematology
|
December 11, 2020
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study
Marie-Charlotte Laude, Laure Lebras, Pierre Sesques, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
Neuro-Oncology
|
March 9, 2016
Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network
Sophie Langner-Lemercier, Caroline Houillier, Carole Soussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2022
Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study
Caroline Houillier, Sylvain Dureau, Luc Taillandier, et al.
The Lancet. Haematology
|
December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with <sup>90</sup>Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial
Françoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.
British Journal of Haematology
|
July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS
Emma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
British Journal of Haematology
|
April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
María Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Oncotarget
|
July 27, 2016
Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
Emilie Reboursiere, Fabien Le Bras, Charles Herbaux, et al.
Blood Advances
|
October 22, 2025
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry
Federico Erbella, Emmannuel Bachy, Guillaume Cartron, et al.
Leukemia
|
September 14, 2022
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML
Arsene Mekinian, Lin Pierre Zhao, Sylvie Chevret, et al.
Page
of 18